The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer

BACKGROUND: Irinotecan (SN38) and oxaliplatin are chemotherapeutic agents used in the treatment of colorectal cancer. However, the frequent development of resistance to these drugs represents a considerable challenge in the clinic. Alus as retrotransposons comprise 11% of the human genome. Genomic t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xue, Stenvang, Jan, Rasmussen, Mads Heilskov, Zhu, Shida, Jensen, Niels Frank, Tarpgaard, Line S, Yang, Guangxia, Belling, Kirstine, Andersen, Claus Lindbjerg, Li, Jian, Bolund, Lars, Brünner, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440512/
https://www.ncbi.nlm.nih.gov/pubmed/25997618
http://dx.doi.org/10.1186/s12864-015-1552-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440512/
https://www.ncbi.nlm.nih.gov/pubmed/25997618
http://dx.doi.org/10.1186/s12864-015-1552-y

Ejemplares similares